Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 158

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 158
---
 meeting. However,    
 the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of at least         
 one shareholder present in person or by proxy.                                                                                             |
| ● | Compensation of officers. Israeli                                                                                                          
 law and our amended and restated articles of association to be in effect upon completion of this offering do not require that the          
 independent members of our board of directors (or a compensation committee composed solely of independent members of our board of          
 directors) determine an executive officer’s compensation, as is generally required under NYSE American Section 805 with respect            
 to the chief executive officer and all other executive officers. Instead, compensation of executive officers is determined and approved    
 by our compensation committee and our board of directors, and in certain circumstances by our shareholders, either in consistency          
 with our office holder compensation policy or, in special circumstances in deviation therefrom, taking into account certain considerations 
 stated in the Companies Law. See “Management—Board Practices—Approval of Related Party Transactions under Israeli                          
 Law” for additional information.                                                                                                           |

| ● | Shareholder approval. We                                                                                                                        
 will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather            
 than seeking approval for corporation actions in accordance with NYSE American rules. In particular, under NYSE American 713, shareholder       
 approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20%                    
 or more of the acquirer’s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest                    
 in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment 
 of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval        
 for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights                   
 (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales               
 by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares.           
 By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) arrangements with directors                 
 and with chief executive officer concerning the terms of